Terbutaline Dosing in Infants
Terbutaline is NOT recommended for infants, as FDA labeling explicitly states it is not recommended for patients under 12 years of age due to insufficient clinical data to establish safety and effectiveness 1, 2.
Critical Safety Concern
The FDA drug labels for terbutaline clearly state: "Terbutaline is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness" 1, 2. This represents the highest level of prescribing guidance and should take precedence over any other considerations.
Guideline-Based Alternatives
The Expert Panel Report 3 (EPR-3) asthma guidelines provide specific dosing for systemic (injected) terbutaline in children, but this is for acute asthma exacerbations, not routine use 3, 4:
Subcutaneous Terbutaline (Emergency Use Only)
- Child dose: 0.01 mg/kg every 20 minutes for 3 doses, then every 2-6 hours as needed
- Maximum: Not specified in guidelines
- Important caveat: Guidelines note "No proven advantage of systemic therapy over aerosol" 3, 4
Why This Matters for Clinical Practice
Nebulized or oral terbutaline formulations are not FDA-approved for infants. The guidelines only reference injectable terbutaline for acute severe asthma in children, and even then, inhaled beta-2 agonists (like albuterol) are strongly preferred 3, 4.
Preferred Approach for Bronchodilation in Infants
For acute wheezing or bronchospasm in infants, use albuterol instead:
- Nebulized albuterol: 0.15 mg/kg (minimum 2.5 mg) every 20 minutes for 3 doses, then 0.15-0.3 mg/kg every 1-4 hours as needed 3, 4
- MDI with spacer: 4-8 puffs every 20 minutes for 3 doses, then every 1-4 hours as needed 3
- Recent meta-analysis confirms inhaled salbutamol (albuterol) is safe in children under 2 years with acute wheeze 5
Research Context (Not for Clinical Recommendation)
While older research studies explored terbutaline in children 6, 7, 8, 9, 10, these do not override the FDA's explicit contraindication for use under age 12. One study used 0.075 mg/kg three times daily orally in children 2-12 years 6, and another used 5 mg nebulized doses in children as young as 19 months 8, but these were research protocols that preceded current FDA labeling restrictions.
Common Pitfalls to Avoid
- Do not extrapolate adult or older child dosing to infants - the FDA restriction exists due to insufficient safety data
- Do not use terbutaline when albuterol is available and appropriate - albuterol has established safety and efficacy in infants
- Do not confuse emergency subcutaneous use in severe asthma with routine nebulized or oral administration - these are different clinical scenarios with different risk-benefit profiles
If bronchodilation is needed in an infant, use albuterol via nebulizer or MDI with spacer as the first-line agent 3, 4, 5.